Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

Hims & Hers thrives with telehealth growth, strong subscriber base, and expanding products, despite challenges like ...

Hims & Hers Health, Inc. (HIMS) closed at $47.96 in the latest trading session, marking a -3.79% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.11%.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

"Wicked” star Cynthia Erivo listed her seven favorite vocal performances of all time, including “Thong Song” by Sisqó!

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...

Novo Nordisk has ended a partnership with telehealth company Him & Hers, after launching the collaboration less than two ...